WallStSmart

Anheuser Busch Inbev NV ADR (BUD)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Anheuser Busch Inbev NV ADR generates 188% more annual revenue ($59.32B vs $20.63B). BUD leads profitability with a 11.5% profit margin vs 10.1%. BUD appears more attractively valued with a PEG of 1.60. BUD earns a higher WallStSmart Score of 61/100 (C+).

BUD

Buy

61

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 10.0Quality: 5.0

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BUDUndervalued (+51.3%)

Margin of Safety

+51.3%

Fair Value

$158.65

Current Price

$68.06

$90.59 discount

UndervaluedFair: $158.65Overvalued
GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BUD5 strengths · Avg: 8.6/10
EPS GrowthGrowth
63.3%10/10

Earnings expanding 63.3% YoY

Market CapQuality
$133.23B9/10

Large-cap with strong market position

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
24.9%8/10

Strong operational efficiency at 24.9%

Free Cash FlowQuality
$9.89B8/10

Generating 9.9B in free cash flow

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Areas to Watch

BUD2 concerns · Avg: 4.0/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.8%4/10

4.8% revenue growth

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BUD

The strongest argument for BUD centers on EPS Growth, Market Cap, Price/Book.

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bear Case : BUD

The primary concerns for BUD are PEG Ratio, Revenue Growth.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

GEHC carries more volatility with a beta of 1.18 — expect wider price swings.

GEHC is growing revenue faster at 7.1% — sustainability is the question.

BUD generates stronger free cash flow (9.9B), providing more financial flexibility.

Monitor BEVERAGES - BREWERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BUD scores higher overall (61/100 vs 60/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Anheuser Busch Inbev NV ADR

CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA

Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?